Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications

Brian Godman, Marie Persson, Jamilette Miranda, Corrado Barbui, Marion Bennie, Alexander E Finlayson, Emanuel Raschi, Bjorn Wettermark

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: Multiple reforms in Sweden appreciably enhanced prescribing efficiency for proton pump inhibitors, statins and renin-angiotensin inhibitor drugs. Potential exists to extend this to atypical antipsychotic drugs (AAPs), given their expenditure and oral generic risperidone available in Sweden from January 2009. However schizophrenia and bipolar disease are complex to treat and there is a need to tailor treatments, given the considerable inter-patient variability in responses and side-effects to different AAPs. Objectives: Assess changes in risperidone utilisation before and after oral generic risperidone reimbursed in January 2009 alongside any specific demand-side measures. In addition, to: (a) assess price reductions for risperidone over time and overall AAP expenditure; (b) suggest additional measures that could potentially be introduced; and (c) provide guidance to other European countries on the implications of any findings. Method: Principally a retrospective observational study and interrupted time series design. Key findings: No specific measures to encourage the prescribing of risperidone, and no appreciable change in its utilisation, after generics reimbursed. Oral risperidone was 96% generic, and its price 80% below pre-patent loss prices, by August 2011. This limited the increase in AAP expenditure compared with utilisation after generics. Conclusion: No apparent effectiveness or safety problems with generic risperidone. Authorities cannot rely on a spill-over from other disease areas to effect changes in physician prescribing habits. Specific measures are needed to encourage the prescribing of generic AAPs first line, where appropriate, exacerbated by the complexity of the disease areas. Their influence will be probably limited by the need to tailor treatment. © 2013 Royal Pharmaceutical Society.
LanguageEnglish
Pages139-150
Number of pages12
JournalJournal of Pharmaceutical Health Services Research
Volume4
Issue number3
Early online date25 Jun 2013
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Risperidone
Sweden
Antipsychotic Agents
Health Expenditures
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Proton Pump Inhibitors
Angiotensins
Drugs
Authority
Renin
Habits
Observational Studies
Schizophrenia
Retrospective Studies
antiarrhythmic peptide
Physicians
Safety
Prescribing
Therapeutics
Pharmaceutical Preparations

Keywords

  • antipsychotics
  • drug utilisation
  • generics
  • reforms
  • risperidone
  • Sweden
  • angiotensin antagonist
  • atypical antipsychotic agent
  • generic drug
  • hydroxymethylglutaryl coenzyme A reductase inhibitor
  • proton pump inhibitor
  • article
  • controlled study
  • drug cost
  • drug efficacy
  • drug utilization
  • growth rate
  • human
  • observational study
  • outcome assessment
  • physician attitude
  • prescription
  • priority journal
  • professional knowledge
  • reimbursement
  • retrospective study

Cite this

Godman, Brian ; Persson, Marie ; Miranda, Jamilette ; Barbui, Corrado ; Bennie, Marion ; Finlayson, Alexander E ; Raschi, Emanuel ; Wettermark, Bjorn. / Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications. In: Journal of Pharmaceutical Health Services Research. 2013 ; Vol. 4, No. 3. pp. 139-150.
@article{fb622ce17b9c4c32ba50d921793b7ebe,
title = "Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications",
abstract = "Introduction: Multiple reforms in Sweden appreciably enhanced prescribing efficiency for proton pump inhibitors, statins and renin-angiotensin inhibitor drugs. Potential exists to extend this to atypical antipsychotic drugs (AAPs), given their expenditure and oral generic risperidone available in Sweden from January 2009. However schizophrenia and bipolar disease are complex to treat and there is a need to tailor treatments, given the considerable inter-patient variability in responses and side-effects to different AAPs. Objectives: Assess changes in risperidone utilisation before and after oral generic risperidone reimbursed in January 2009 alongside any specific demand-side measures. In addition, to: (a) assess price reductions for risperidone over time and overall AAP expenditure; (b) suggest additional measures that could potentially be introduced; and (c) provide guidance to other European countries on the implications of any findings. Method: Principally a retrospective observational study and interrupted time series design. Key findings: No specific measures to encourage the prescribing of risperidone, and no appreciable change in its utilisation, after generics reimbursed. Oral risperidone was 96{\%} generic, and its price 80{\%} below pre-patent loss prices, by August 2011. This limited the increase in AAP expenditure compared with utilisation after generics. Conclusion: No apparent effectiveness or safety problems with generic risperidone. Authorities cannot rely on a spill-over from other disease areas to effect changes in physician prescribing habits. Specific measures are needed to encourage the prescribing of generic AAPs first line, where appropriate, exacerbated by the complexity of the disease areas. Their influence will be probably limited by the need to tailor treatment. {\circledC} 2013 Royal Pharmaceutical Society.",
keywords = "antipsychotics, drug utilisation, generics, reforms, risperidone, Sweden, angiotensin antagonist, atypical antipsychotic agent, generic drug, hydroxymethylglutaryl coenzyme A reductase inhibitor, proton pump inhibitor, article, controlled study, drug cost, drug efficacy, drug utilization, growth rate, human, observational study, outcome assessment, physician attitude, prescription, priority journal, professional knowledge, reimbursement, retrospective study",
author = "Brian Godman and Marie Persson and Jamilette Miranda and Corrado Barbui and Marion Bennie and Finlayson, {Alexander E} and Emanuel Raschi and Bjorn Wettermark",
year = "2013",
month = "9",
doi = "10.1111/jphs.12025",
language = "English",
volume = "4",
pages = "139--150",
journal = "Journal of Pharmaceutical Health Services Research",
issn = "1759-8885",
number = "3",

}

Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications. / Godman, Brian; Persson, Marie; Miranda, Jamilette; Barbui, Corrado; Bennie, Marion; Finlayson, Alexander E; Raschi, Emanuel; Wettermark, Bjorn.

In: Journal of Pharmaceutical Health Services Research, Vol. 4, No. 3, 09.2013, p. 139-150.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications

AU - Godman, Brian

AU - Persson, Marie

AU - Miranda, Jamilette

AU - Barbui, Corrado

AU - Bennie, Marion

AU - Finlayson, Alexander E

AU - Raschi, Emanuel

AU - Wettermark, Bjorn

PY - 2013/9

Y1 - 2013/9

N2 - Introduction: Multiple reforms in Sweden appreciably enhanced prescribing efficiency for proton pump inhibitors, statins and renin-angiotensin inhibitor drugs. Potential exists to extend this to atypical antipsychotic drugs (AAPs), given their expenditure and oral generic risperidone available in Sweden from January 2009. However schizophrenia and bipolar disease are complex to treat and there is a need to tailor treatments, given the considerable inter-patient variability in responses and side-effects to different AAPs. Objectives: Assess changes in risperidone utilisation before and after oral generic risperidone reimbursed in January 2009 alongside any specific demand-side measures. In addition, to: (a) assess price reductions for risperidone over time and overall AAP expenditure; (b) suggest additional measures that could potentially be introduced; and (c) provide guidance to other European countries on the implications of any findings. Method: Principally a retrospective observational study and interrupted time series design. Key findings: No specific measures to encourage the prescribing of risperidone, and no appreciable change in its utilisation, after generics reimbursed. Oral risperidone was 96% generic, and its price 80% below pre-patent loss prices, by August 2011. This limited the increase in AAP expenditure compared with utilisation after generics. Conclusion: No apparent effectiveness or safety problems with generic risperidone. Authorities cannot rely on a spill-over from other disease areas to effect changes in physician prescribing habits. Specific measures are needed to encourage the prescribing of generic AAPs first line, where appropriate, exacerbated by the complexity of the disease areas. Their influence will be probably limited by the need to tailor treatment. © 2013 Royal Pharmaceutical Society.

AB - Introduction: Multiple reforms in Sweden appreciably enhanced prescribing efficiency for proton pump inhibitors, statins and renin-angiotensin inhibitor drugs. Potential exists to extend this to atypical antipsychotic drugs (AAPs), given their expenditure and oral generic risperidone available in Sweden from January 2009. However schizophrenia and bipolar disease are complex to treat and there is a need to tailor treatments, given the considerable inter-patient variability in responses and side-effects to different AAPs. Objectives: Assess changes in risperidone utilisation before and after oral generic risperidone reimbursed in January 2009 alongside any specific demand-side measures. In addition, to: (a) assess price reductions for risperidone over time and overall AAP expenditure; (b) suggest additional measures that could potentially be introduced; and (c) provide guidance to other European countries on the implications of any findings. Method: Principally a retrospective observational study and interrupted time series design. Key findings: No specific measures to encourage the prescribing of risperidone, and no appreciable change in its utilisation, after generics reimbursed. Oral risperidone was 96% generic, and its price 80% below pre-patent loss prices, by August 2011. This limited the increase in AAP expenditure compared with utilisation after generics. Conclusion: No apparent effectiveness or safety problems with generic risperidone. Authorities cannot rely on a spill-over from other disease areas to effect changes in physician prescribing habits. Specific measures are needed to encourage the prescribing of generic AAPs first line, where appropriate, exacerbated by the complexity of the disease areas. Their influence will be probably limited by the need to tailor treatment. © 2013 Royal Pharmaceutical Society.

KW - antipsychotics

KW - drug utilisation

KW - generics

KW - reforms

KW - risperidone

KW - Sweden

KW - angiotensin antagonist

KW - atypical antipsychotic agent

KW - generic drug

KW - hydroxymethylglutaryl coenzyme A reductase inhibitor

KW - proton pump inhibitor

KW - article

KW - controlled study

KW - drug cost

KW - drug efficacy

KW - drug utilization

KW - growth rate

KW - human

KW - observational study

KW - outcome assessment

KW - physician attitude

KW - prescription

KW - priority journal

KW - professional knowledge

KW - reimbursement

KW - retrospective study

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84881664450&partnerID=40&md5=f5f8b87492562db0d80ed9d93d2fcf81

U2 - 10.1111/jphs.12025

DO - 10.1111/jphs.12025

M3 - Article

VL - 4

SP - 139

EP - 150

JO - Journal of Pharmaceutical Health Services Research

T2 - Journal of Pharmaceutical Health Services Research

JF - Journal of Pharmaceutical Health Services Research

SN - 1759-8885

IS - 3

ER -